

Yearly update of advances in medical oncology 2017

20-21 Απριλίου 2018
Divani Palace Acropolis Hotel
Αθήνα



Υπό την Αιγίδα των:



Ελληνική
Εταιρεία
Παθολογικής
Ανατομικής

ΕΟΠΕ
ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ
ΟΡΓΑΝΩΣΗΣ ΠΡΟΓΝΩΣΤΙΚΗΣ
ΕΚΠΑΙΔΕΥΣΗΣ

Οργάνωση

ΕΛΛΗΝΙΚΟ
FORUM
ΟΓΚΟΛΟΓΙΑΣ

Θα χορηγηθούν μέρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME - CPD credits)
ΔΗΛΩΣΕΙΣ ΣΥΜΜΕΤΟΧΗΣ στο info@scep.gr

Χαιρετισμός

Αγαπητοί συνάδελφοι και φίλοι,

Με ιδιαίτερη χαρά σας προσκαλούμε στη Διημερίδα με τίτλο «**Yearly update of Advances in Medical Oncology 2016**» που διοργανώνεται από το Ελληνικό Forum Ογκολογίας.

Το σύνολο της ετήσιας δημοσιευόμενης βιβλιογραφίας που αφορά την ογκολογία είναι τεράστια, καθιστώντας εκ των πραγμάτων προβληματική την καθημερινή και σε βάθος παρακολούθησή της. Λαμβάνοντας υπόψη τη θετική ανταπόκριση που είχε το ανάλογο εγχείρημα πέρυσι, αποφασίσθηκε για δεύτερη συνεχή χρονιά να παρουσιασθούν οι πιο σημαντικές ογκολογικές μελέτες που έχουν δημοσιευθεί ως πλήρη άρθρα σε περιοδικά με υψηλό impact factor μέσα στο 2017, σε ένα εντατικό διήμερο.


Μία ομάδα έμπειρων συναδέλφων επέλεξε άρθρα, τα οποία δίνουν ουσιαστικές προοπτικές αλλαγής της καθημερινής ογκολογικής πρακτικής.

Ο στόχος είναι, μέσω της αναλυτικής παρουσίασης των μελετών και το σχολιασμό τους, να βελτιωθεί η κλινική γνώση και η ποιότητα της καθημερινής πρακτικής.

Ευχαριστούμε πολύ για τη συμμετοχή σας.

Εκ μέρους της Οργανωτικής Επιτροπής

Παναγιώτης Κατσαούνης



MD, MSc, Παθολόγος - Ογκολόγος
Επιμελητής Α' Ογκολογικό Τμήμα,
«ΙΑΣΩ General», Αθήνα
Πρόεδρος Επιστημονικής Επιτροπής

Βασίλειος Γεωργούλιας



Ομότιμος Καθηγητής Παθολογίας Ογκολογίας
Ιατρική Σχολή Πανεπιστημίου Κρήτης
Πρόεδρος Οργανωτικής Επιτροπής

Οργανωτική Επιτροπή

Β. Γεωργούλιας
Π. Κατσαούνης

Επιστημονική Επιτροπή

Πρόεδρος

Π. Κατσαούνης

Μέλη

Α. Αργύρης
Χ. Εμμανουηλίδης
Ζ. Ζαφειρίου
Ν. Κεντεποζίδης
Α. Κουμαριανού
Π. Κουντουράκης
Α. Κούτρα
Α. Κουτσόπουλος
Ε. Λιανίδου
Ε. Ραζή
Ε. Τιμοθεάδου
Μ. Τόλια

CYRAMZA® (ramucirumab)

TAKE ACTION



TRAINED TO MAKE A DIFFERENCE ABLE TO MAKE AN IMPACT

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΑΕΣ τις ανεπιθύμητες ενέργειες για ΟΑΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Για περισσότερες πληροφορίες απευθυνθείτε στην Εταιρεία



GASTRIC



NSCLC



CRC

Yearly update of advances in medical oncology 2017

Friday, April 20th, 2018

08.00-09.00 Registration

09.00-09.45 **Session 1: General Issues**

Moderators: **Ch. Emmanouilides, S. Xynogalos**

09.00-09.15 ▶ Mediterranean diet and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition cohort

E. Ntouvelis

▶ ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia

▶ Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma

09.15-09.30 ▶ Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial

K. Rapti

▶ Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?

▶ Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study

09.30-09.45 Q & A and Comments

09.45-10.30 **SESSION 2: CIRCULATING BIOMARKERS (CTCs and ctDNA)**

Moderators: **A. Markou, V. Georgoulas**

09.45- 10.00 ▶ Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study

E. Tzanikou

▶ Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

▶ ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment

10.00-10.15 ▶ Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma

A. Markou

▶ Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease

▶ Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients

10.15-10.30 Q & A and Comments

10.30-11.00 Coffee break



ΦΑΡΜΑΞΕΡΒ - LILLY A.E.B.E.

15ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας, 14564 Κηφισιά **ΤΗΛ.**: 210 6294600 **Fax**: 210 6294610
Για παραγγελίες: **ΤΗΛ.**: 210 6294629 **Fax**: 210 6294630 **e-mail**: orders@lilly.gr www.lilly.gr



TAGRISSO (osimertinib)

Όνομασία του φαρμακευτικού προϊόντος:

TAGRISSO 40 mg επικαλυμμένα με λεπτό υμένιο δισκία

TAGRISSO 80 mg επικαλυμμένα με λεπτό υμένιο δισκία

Ποιοτική και ποσοτική σύνθεση:

TAGRISSO 40 mg Δισκία. Κάθε δισκίο περιέχει 40 mg οσιμερτινίμπης (ως μεσυλικής).

TAGRISSO 80 mg Δισκία. Κάθε δισκίο περιέχει 80 mg οσιμερτινίμπης (ως μεσυλικής).

Για περισσότερες συνταγογραφικές πληροφορίες απευθυνθείτε στην εταιρεία AstraZeneca A.E.

▼ Τα φάρμακα αυτά πωλούνται υπό αυστηρή ιατρική παρακολούθηση. Αυτό θα επιτρέψει τον γρήγορο προσδιορισμό νέων πληροφοριών ασφαλείας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιαδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες στον Εθνικό Οργανισμό Φαρμάκων, Μεσογείων 284 G6-15562 Χαλάνδρι, Αθήνα, Τηλ: + 30 21 32040380/337, Φαξ: + 30 21 06549585, Ιστοσελίδα: <http://www.eof.gr>



Θεοτοκοπούλου 4 & Αστροναυτών, 151 25 Μαρούσι, Αθήνα
Τηλ.: 210 6871500, Fax: 210 6859195
Τηλ. παραγγελιών: 216 2000000, Fax: 210 5596973
www.astrazeneca.gr

11.00-12.00 Session 3: Head and Neck Cancers

Moderators: **A. Argiris, M. Balafouta**

- 11.00-11.15 ▶ Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer
- ▶ Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
- ▶ Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- 11.15-11.30 ▶ Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- ▶ Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial
- ▶ Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

M. Bakogeorgos

M. Rovithi

- 11.30-11.45 ▶ What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis

C. Avgerinou

- ▶ Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study
- ▶ Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

- 11.45-12.00 Q & A and Comments

12.00-13.00 Session 4: Colorectal tumors

Moderators: **A. Koumariannou, P. Kountourakis**

- 12.00-12.15 ▶ Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
- ▶ Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2
- ▶ Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
- 12.15-12.30 ▶ TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

A. Vagionas

K. Tsigaridas

- ▶ Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
- ▶ Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

10 years

BINO CRIT
epoetin alfa

BINO CRIT
epoetin alfa

Πριν τη συνταγογράφηση συμβουλευθείτε
τον Παιδίατρο Χειρουργο-Ογκολόγο της Βασίδας

Ενδείξεις: αν γίνετε το παιδί σας νοσηλεία
στη Βασίδα ή αν νοσηλεύεται στο σπίτι
στον Ε.Σ.Α. ή στο σπίτι
Συμπλήρωση των «ΕΠΙΧΕΙΡΗΜΑΤΩΝ»

- 12.30-12.45 ▶ Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database **G. Lambrodimou**
- ▶ Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
- ▶ Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
- 12.45-13.00 Q & A and Comments
- 13.00-14.30 **Lunch**
- 14.30-15.45 **Session 5: CNS, Genetics**
Moderators: **E. Razi, A. Koutsopoulos**
- 14.30-14.50 ▶ Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma **G. Rigakos**
- ▶ Lomustine and Bevacizumab in Progressive Glioblastoma
- ▶ Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- 14.50-15.10 ▶ Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer **P. Koulouris**
- ▶ Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers
- ▶ Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma
- 15.10-15.30 ▶ MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values **K. Tsapakidis**
- ▶ Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
- ▶ Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
- 15.30-15.45 Q & A and Comments
- 15.45-17.00 **Session 6: Breast Cancer**
Moderators: **A. Koutras, D. Tryfonopoulos**
- 15.45-16.05 ▶ Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy **M. Theochari**
- ▶ Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- ▶ Utidalone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
- 16.05-16.25 ▶ Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation **S. Karageorgopoulou**
- ▶ Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients
- ▶ MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

AVASTIN®



Roche (Hellas) A.E.
Αιολώνος 4 & Δελφών 151 25 Μαρούσι, Αττική
τηλ. 210 6166100, fax: 210 6166159
email: hellas.medinfo@roche.com
τηλ. 800 111 93 00 Ειδικά ιδιωτών γραμμή επικοινωνίας
τηλ. 800 92 668 Κύριος (Ιδιωτών γραμμή επικοινωνίας)

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Ανοφέρετε
**ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα**
Συμπληρώστε την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Η εταιρεία Roche Hellas A.E είναι πιστοποιημένη με ISO 9001:2008



Επισκεφθείτε την ιστοσελίδα του **AVASTIN®**
στο www.rochemed.gr

Avastin 25mg/ml υδατικό διάλυμα για παρεντερική διαχείριση προς έγχυση

Παραίτητοι πληροφορίες διατίθενται από την εταιρεία
Roche Hellas A.E., κατόνιν αιτήσεως



AVASTIN®

bevacizumab

16.25-16.45 ▶ Oral Bisphosphonates and Improved Survival of Breast Cancer

E. Moirgiorgou

▶ Trastuzumabemtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

▶ Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

16.45-17.00 Q & A and Comments

17.00-17.30 Coffee break

17.30-18.45 **Session 7: Sarcoma-Melanoma**

Moderators: E. Lagoudaki, Ch. Kosmas

17.30-17.50 ▶ Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

A. Laskarakis

▶ Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

▶ Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

17.50-18.10 ▶ Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

N. Diamantopoulos

▶ Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

▶ Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

18.10-18.30 ▶ Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

K. Stouraiti

▶ A phase II study of a human anti-PDGFRA monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

▶ Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE

18.30-18.45 Q & A and Comments

18.45-20.00 **Session 8: Upper GI Tumors**

Moderators: N. Kentepozidis, A. Karampeazis

18.45-19.05 ▶ Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

M. Paraskeva

▶ Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

- 19.05-19.25 ▶ Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
- 19.05-19.25 ▶ Whole-genome landscape of pancreatic neuroendocrine tumours
- ▶ Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- ▶ Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial
- 19.25-19.45 ▶ Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- ▶ CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- ▶ Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base
- 19.45-20.00 Q & A and Comments
- 20.00-21.00 **Session 9: Gynecological Cancer**
Moderators: **E. Timotheadou, C. Christofyllakis**
- 20.00-20.20 ▶ Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- ▶ Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- ▶ Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- 20.20-20.40 ▶ Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- ▶ Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
- ▶ Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
- 20.40-21.00 Q & A and Comments

E. Lagoudaki

I. Kotsantis

S. Kaltsas

E. Maragouli

SATURDAY, April 21st, 201809.10-10.00 **Session 10: Biomarkers**Moderators: **I. Pateras, A. Koutsopoulos**

- 09.10-09.30 ▶ A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer
- ▶ A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity
- 09.30-09.50 ▶ Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
- ▶ Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology and the American Society of Clinical Oncology
- 09.50-10.00 Q & A and Comments
- 10.00-11.15 **Session 11: Urogenital Cancer**
Moderators: **Z. Zafeirolou, N. Alevizopoulos**
- 10.00-10.20 ▶ Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
- ▶ Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- ▶ Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- 10.20-10.40 ▶ Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
- ▶ Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
- ▶ A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- 10.40-11.00 ▶ Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- ▶ Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- ▶ Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial - FIRSTANA
- 11.00-11.15 Q & A and Comments
- 11.15-12.00 **Coffee break**

A. Tzovaras

V. Ramfidis

E. Lianos

N. Pavlidis

E. Bournakis

12.00–13.00 Session 12: Immuno-Oncology and ImmunotherapyModerators: **A. Kotsakis, K. Vetsika****12.00–12.20** ▶ Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1**N. Tsoukalas**

▶ Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy

▶ The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

12.20–12.40 ▶ An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer**E. Eleftherakis-Papaiaikovou**

▶ Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

▶ Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy

12.40–13.00 Q & A and Comments**13.00–14.30 Lunch****14.30–16.20 Session 13: Lung Cancer**Moderators: **A. Kotsakis, P. Katsaounis****14.30–14.50** ▶ Phase III Impower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy**P. Katsaounis**

▶ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

▶ Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

14.50–15.10 ▶ Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer**E. Kontopodis**

▶ Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

▶ Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

15.10–15.30 ▶ Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial**F. Koinis**

▶ Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

▶ Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

15.30–15.50 ▶ Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies**M. Nikolaou**

▶ Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer – A Multicenter Retrospective Study

▶ Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

15.50–16.20 Q & A and Comments**16.20–17.45 Session 14: Radiotherapy**Moderators: **I. Georgakopoulos, M. Tolia****16.20–16.40** ▶ Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial**A. Giannopoulou**

▶ Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial

▶ Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001

16.40–17.00 ▶ Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials**A. Stergioula**

▶ Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial

▶ Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study

17.00–17.20 ▶ Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database**A. Gantaifi**

▶ Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer

▶ Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer

17.20–17.45 Q & A and Comments**17.45–18.45 Closing Remarks**

Ευρετήριο Ομιλητών-Προέδρων

Alevizopoulos Nektarios MD, Medical Oncologist, Evangelismos General Hospital, Athens, Greece

Argiris Athanasios MD, PhD, FACP, Consultant Medical Oncologist, Hygeia Hospital, Athens, Greece, Professor, Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA, Adjunct Professor, University of Texas Health Science Center at San Antonio, Texas, USA

Avgerinou Chrysanthi Medical Oncology Resident, Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, Athens, Greece

Bakogeorgos Marios Medical Oncologist, 251 Hellenic Airforce General Hospital, Athens, Greece

Balafouta Myrsini Radiotherapist Oncologist, Lecturer University of Athens, Greece

Bournakis Evangelos MD, Medical Oncologist, Scientific Associate Oncology Unit Areteio University Hospital of Athens, Iaso General Clinic of Athens, Greece

Christofyllakis Charalampos Director of the Department of Medical Oncology, 401 General Military Hospital of Athens, Greece

Diamantopoulos Nikolaos Medical Oncologist, A' Dpt of Medical Oncology, Theagenio Hospital, Thessaloniki, Greece

Eleutherakis-Papaiaikovou Evangelos MD, PhD, Medical Oncologist, Locum Consultant at Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece

Emmanouilides Christos MD, PhD, Professor of Medical Oncology, Dept. of Hematology & Medical Oncology, UCLA, CA, USA & European Interbalkan Medical Center, Thessaloniki, Greece

Gantaifi Areti MD, Radiation Oncologist, Interbalkan Medical Center, Thessaloniki, Greece

Georgakopoulos Ioannis Radiation Oncologist, 401 Military Hospital, IASO Hospital, Athens, Greece

Georgoulas Vasileios Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Greece

Giannopoulou Alexandra MD, MSc, Radiation Oncologist, IASO Radiotherapy Department, Athens, Greece

Kaltsas Serafeim Medical Oncologist, Consultant 3rd Oncologic Clinic Metropolitan Hospital, Athens, Greece

Karageorgopoulou Sofia MD, Medical Oncologist, IASO Clinic, Medical Oncology Department

Karampeazis Athanasios MD, Medical Oncology Consultant, 401 Army General Hospital, Athens, Greece

Katsaounis Panagiotis MD, Medical Oncologist, 1st Oncology Unit, IASO General, Athens, Greece

Kentepozidis Nikolaos M.D, PhD, Medical Oncologist, Head of Oncology Clinic, 251 General Airforce Hospital, Athens, Greece

Koinis Phillipos Consultant Medical Oncologist, Iatriko Athinon, Scientific Associate, Member of the Molecular Carcinogenesis Group, Laboratory of Histology and Embryology Medical School, National and Kapodistrian University of Athens

Kontopodis Emmanouil MD, Medical Oncologist, Venizeleion General Hospital of Heraklion

Kosmas Christos MD, PhD, Consultant Medical Oncologist & Head Hematopoietic Cell Transplant Unit, Department of Medicine, «Metaxa» Cancer Hospital, Piraeus, Greece

Kotsakis Athanasios MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, General University Hospital of Larissa

Kotsantis Ioannis MD, Medical Oncologist, Oncology Unit, 2nd Department of Internal Medicine, ATTIKON University Hospital, Athens, Greece

Koulouris Andreas MD, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece

Koumariannou Anna MD, PhD in Tumor Immunotherapies, Imperial College, Consultant in Medical Oncology, Hematology-Oncology Unit, ENETs Centre of Excellence, Fourth Department of Internal Medicine, Attikon University Hospital, Athens, Greece

Kountourakis Panteleimon MD, PhD, Consultant Medical Oncologist, Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

Koutras Aggelos Assistant Professor in Medical Oncology, University of Patras, Greece

Koutsopoulos Anastasios MD, PhD, Assistant Professor of Pathology, Faculty of Medicine, University of Crete, Laboratory of Pathology, University Hospital of Heraklion, Heraklion, Crete, Greece

Lagoudaki Eleni MD, Consultant in Pathology, University Hospital of Heraklion, Heraklion, Crete

Lambrodinou Georgia Medical Oncologist, "Metaxa Cancer Hospital", Piraeus, Greece

Laskarakis Apostolos MD, MSc, Medical Oncologist, Consultant at 1st Oncology Clinic, Metropolitan Hospital of Athens, Greece

Lianos Evangelos MD, Consultant of Medical Oncology, Dpt METAXA Memorial Cancer Center Hospital, Piraeus, Greece

Maragouli Eleni MD, Medical Oncologist, University of Thessaly, Biologist, Aristotle University of Thessaloniki, Greece

Markou Athina PhD, Postdoctoral Researcher, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, University of Athens, Athens, Greece

Moirogiorgou Evangelia Medical Oncologist, Hygeia Hospital, Athens, Greece

Nikolaou Michail MD, MSc, PhD, Medical Oncologist, General and Maternity Hospital "Elena Venizelou", Athens, Greece

Ntouvelis Evangelos MD, PhD, Medical Oncologist, Corfu General Clinic, Corfu, Greece.

Paraskeva Maria Medical Oncologist, General Hospital of Rhodes, Rhodes, Greece

Pateras Ioannis Assistant Professor, Bsc, MD, PhD, Pathologist, Molecular Carcinogenesis Group, Laboratory of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Pavlidis Nektarios MD, MSc, Medical Oncologist, University Hospital of Lausanne, Swiss

Ramfidis Vasileios MD, MSc, Consultant Medical Oncologist, Dpt. of Medical Oncology, 251 Airforce General Hospital of Athens, Greece

Rapti Kleopatra MD, MSc, Consultant Medical Oncologist, Department of Medical Oncology, 251 Airforce General Hospital of Athens, Greece

Razis Evangelia MD, PhD, Medical Oncologist, Director 3rd Oncology Department, Hygeia Hospital, Athens, Greece

Rigakos Georgios MD MSc, Medical oncologist, 3rd oncology department, Hygeia Hospital, Athens, Greece

Rovithi Maria Medical Oncology Unit, Dpt of Internal Medicine, Agios Nikolaos G. Hospital, Crete, Greece

Stergioula Anastasia Radiation Oncologist, Department of Radiation Oncology "Iaso", Athens, Greece

Stouraiti Kalliopi Medical Oncologist, Euroclinic of Athens, Athens, Greece

Theochari Maria MD, Consultant B' of Medical Oncology, Oncology Unit, Hippokrateion University Hospital, Athens, Greece

Timotheadou Eleni MD, PhD, Assistant Professor of Medicine Oncology, Aristotle University Of Thessaloniki, Greece

Tolia Maria MD, Msc, PhD, Assistant Professor of Radiotherapy, Radiotherapy/Radiation Oncology Dept, Faculty of Medicine, School of Health Sciences, University of Thessaly - University Hospital of Larissa, Greece

Tryfonopoulos Dimitrios Consultant Medical Oncologist, St. Savas Anticancer Hospital, Athens, Greece

Tsapakidis Konstantinos Medical Oncologist, University Hospital of Larissa, Greece

Tsigaridas Konstantinos Medical Oncologist, A' Oncology Unit, Metropolitan Hospital of Athens, Greece

Tsoukalas Nikolaos MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Consultant at Veterans Hospital (NIMTS), Athens Greece

Tzanikou Eleni PhD candidate, Laboratory of Analytical Chemistry, Analysis of Circulating Tumor Cells (ACTC) Lab, Dept of Chemistry, University of Athens, Athens, Greece

Tzovaras Alexandros PhD, Medical Oncologist, Henry Dynnant Hospital, Athens Medical Center, Athens, Greece

Vagionas Anastasios Medical Oncologist, University General Hospital of Thessaloniki "AHEPA", 1st Propaedeutic Internal Medicine Dpt /Oncology Day Unit, Thessaloniki, Greece

Vetsika Eleni-kyriaki MPhil, PhD, Biochemist, Research Associate, Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece

Xynogalos Spyridon MD, PhD, Consultant Medical Oncologist, Metaxa Memorial Cancer Hospital, Piraeus, Greece

Zafeiriou Zafeiris MD, MSc, Medical Oncologist, Theageneion Anticancer Hospital, Thessaloniki, Greece

Yearly update of advances in medical oncology 2017

Γενικές πληροφορίες

Διοργάνωση



Ημερομηνία Διεξαγωγής

20-21 Απριλίου 2018

Χώρος Διεξαγωγής

Ξενοδοχείο, Divani Palace Acropolis Hotel,
Παρθενώνος 19, Αθήνα, ΤΚ:117 42
Τηλέφωνο: 210 9280100

Υπό την Αιγίδα



Εγγραφή

Η εγγραφή στη Διημερίδα είναι δωρεάν

Γλώσσα

Η επίσημη γλώσσα της διημερίδας θα είναι η Ελληνική

Πιστοποιητικό Παρακολούθησης

Το Πιστοποιητικό Παρακολούθησης θα δοθεί στους συμμετέχοντες μετά το πέρας των εργασιών της Διημερίδας. Βάσει της τελευταίας εγκυκλίου του ΕΟΦ, θα υπάρχει σύστημα καταμέτρησης του χρόνου παρακολούθησης. Η πιστοποίηση παρακολούθησης θα δίνεται σε όσους έχουν συμπληρώσει τουλάχιστον το 60% των συνολικών ωρών του προγράμματος. Ο αριθμός Μορίων της Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME-CPD) που θα χορηγηθεί στους συμμετέχοντες, θα υπολογιστεί βάσει χρόνου παρακολούθησης. Η διημερίδα μοριοδοτείται με μόρια (Credits) Συνεχιζόμενης Ιατρικής Εκπαίδευσης.

Γραμματεία Διημερίδας



Scientific | Cultural Events and Publications

T+30 2810 222155. +30 210 7240039

F+30 2810 222156, +30 210 7240139

E info@scep.gr

www.scep.qr

Σημειώσεις

The image is a collage of various journal covers from the American Society of Clinical Oncology (ASCO) family. The covers are arranged in a way that they overlap and are set against a background of light gray geometric shapes, including circles, triangles, and diamonds. The journals visible include:

- JOURNAL OF CLINICAL ONCOLOGY**: The top left cover features a microscope icon and the ASCO logo.
- Clinical Cancer Research**: A cover on the right side with a dark background and white text.
- Journal of Clinical Oncology**: A cover in the center with a grid pattern and various text elements.
- Journal of Thoracic Oncology**: A cover at the bottom right with a dark background and a small image of a person.

The overall design is modern and professional, reflecting the scientific nature of the publications.

Χορηγοί

Ευχαριστούμε θερμά τις παρακάτω εταιρείες για την ουσιαστική συμβολή τους, στην πραγματοποίηση του συνεδρίου



Η σειρά καταχώρησης των εταιρειών είναι κατά αλφαβητική σειρά

Σημειώσεις

Journal of Clinical Oncology

ANNALS OF ONCOLOGY

Clinical Research

Journal of Thoracic Oncology

Changing tomorrow



Η Astellas είναι αφοσιωμένη στο να μετατρέψει την επιστημονική καινοτομία σε ιατρικές λύσεις που αποφέρουν αξία και ελπίδα στους ασθενείς παγκοσμίως.

Δεσμευόμαστε να καταπολεμήσουμε τον καρκίνο και να διαθέσουμε καινοτόμες θεραπείες που μπορούν να παρατείνουν και να βελτιώσουν τη ζωή των ανθρώπων που πάσχουν από καρκίνο.

Για να το πετύχουμε αυτό, εστιάζουμε τις προσπάθειές μας σε τομείς όπου μπορούμε να αναπτύξουμε τα καλύτερα φάρμακα στην κατηγορία τους και εκεί όπου υπάρχουν πραγματικές θεραπευτικές ανάγκες για τους ασθενείς.

Κατά συνέπεια ένας σημαντικός αριθμός μορίων είναι ήδη σε φάση κλινικής ανάπτυξης ενώ πολλά περισσότερα βρίσκονται ακόμα σε πρώιμο ερευνητικό στάδιο.

Στην Astellas, εστιάζουμε στο να κάνουμε πραγματικότητα το αλλόζοντας το αύριο.

astellas.gr



© September 2017 Astellas Pharmaceuticals A.E.E. GR/PH/CO/17.0004

